OBJECTIVE: To compare bone mass between overweight adolescents with and without cardiometabolic risk factors (CMR). Associations of bone mass with CMR and adiposity were also determined. STUDY DESIGN: Adolescents (aged 14 to 18 years) who were overweight were classified as healthy (n = 55), having one CMR (1CMR; n = 46), or having two or more CMR (≥2CMR; n = 42). CMRs were measured with standard methods and defined according to pediatric definitions of metabolic syndrome. Total body bone mass, fat mass, and fat-free soft tissue mass were measured with dual-energy X-ray absorptiometry. Visceral adipose tissue and subcutaneous abdominal adipose tissue were assessed with magnetic resonance imaging. RESULTS: After controlling for age, sex, race, height, and fat-free soft tissue mass, the healthy group had 5.4% and 6.3% greater bone mass than the 1CMR and ≥2CMR groups, respectively (both P values <.04). With multiple linear regression, adjusting for the same co-variates, visceral adipose tissue (β = -0.22), waist circumference (β = -0.23), homeostasis model assessment of insulin resistance (β = -0.23), and high-density lipoprotein cholesterol level (β = 0.22) were revealed to be associated with bone mass (all P values <.04). There was a trend toward a significant inverse association between bone mass and fasting glucose level (P = .056). No relations were found between bone mass and fat mass, subcutaneous abdominal adipose tissue, blood pressure, or triglyceride level. CONCLUSION: Being overweight with metabolic abnormalities, particularly insulin resistance, low high-density lipoprotein cholesterol level, and visceral adiposity, may adversely influence adolescent bone mass.
OBJECTIVE: To compare bone mass between overweight adolescents with and without cardiometabolic risk factors (CMR). Associations of bone mass with CMR and adiposity were also determined. STUDY DESIGN: Adolescents (aged 14 to 18 years) who were overweight were classified as healthy (n = 55), having one CMR (1CMR; n = 46), or having two or more CMR (≥2CMR; n = 42). CMRs were measured with standard methods and defined according to pediatric definitions of metabolic syndrome. Total body bone mass, fat mass, and fat-free soft tissue mass were measured with dual-energy X-ray absorptiometry. Visceral adipose tissue and subcutaneous abdominal adipose tissue were assessed with magnetic resonance imaging. RESULTS: After controlling for age, sex, race, height, and fat-free soft tissue mass, the healthy group had 5.4% and 6.3% greater bone mass than the 1CMR and ≥2CMR groups, respectively (both P values <.04). With multiple linear regression, adjusting for the same co-variates, visceral adipose tissue (β = -0.22), waist circumference (β = -0.23), homeostasis model assessment of insulin resistance (β = -0.23), and high-density lipoprotein cholesterol level (β = 0.22) were revealed to be associated with bone mass (all P values <.04). There was a trend toward a significant inverse association between bone mass and fasting glucose level (P = .056). No relations were found between bone mass and fat mass, subcutaneous abdominal adipose tissue, blood pressure, or triglyceride level. CONCLUSION: Being overweight with metabolic abnormalities, particularly insulin resistance, low high-density lipoprotein cholesterol level, and visceral adiposity, may adversely influence adolescent bone mass.
Authors: Catherine M Gordon; Laura K Bachrach; Thomas O Carpenter; Nicola Crabtree; Ghada El-Hajj Fuleihan; Stepan Kutilek; Roman S Lorenc; Laura L Tosi; Katherine A Ward; Leanne M Ward; Heidi J Kalkwarf Journal: J Clin Densitom Date: 2008 Jan-Mar Impact factor: 2.617
Authors: Karen S Wosje; Philip R Khoury; Randal P Claytor; Kristen A Copeland; Heidi J Kalkwarf; Stephen R Daniels Journal: J Pediatr Date: 2008-08-09 Impact factor: 4.406
Authors: William D Johnson; Jolanda J M Kroon; Frank L Greenway; Claude Bouchard; Donna Ryan; Peter T Katzmarzyk Journal: Arch Pediatr Adolesc Med Date: 2009-04
Authors: Eiichi Hinoi; Nan Gao; Dae Young Jung; Vijay Yadav; Tatsuya Yoshizawa; Martin G Myers; Streamson C Chua; Jason K Kim; Klaus H Kaestner; Gerard Karsenty Journal: J Cell Biol Date: 2008-12-22 Impact factor: 10.539
Authors: Raquel M S Campos; Aline de Piano; Patrícia L da Silva; June Carnier; Priscila L Sanches; Flávia C Corgosinho; Deborah C L Masquio; Marise Lazaretti-Castro; Lila M Oyama; Cláudia M O Nascimento; Lian Tock; Marco Túlio de Mello; Sergio Tufik; Ana R Dâmaso Journal: Endocrine Date: 2012-08 Impact factor: 3.633
Authors: Lisa B Rokoff; Sheryl L Rifas-Shiman; Karen M Switkowski; Jessica G Young; Clifford J Rosen; Emily Oken; Abby F Fleisch Journal: Bone Date: 2018-12-15 Impact factor: 4.398
Authors: Emma M Laing; Ralph A Tripp; Norman K Pollock; Clifton A Baile; Mary Anne Della-Fera; Srujana Rayalam; Stephen M Tompkins; Deborah A Keys; Richard D Lewis Journal: J Bone Miner Res Date: 2013-03 Impact factor: 6.741
Authors: J M Kindler; N K Pollock; E M Laing; N T Jenkins; A Oshri; C Isales; M Hamrick; R D Lewis Journal: J Clin Endocrinol Metab Date: 2015-11-17 Impact factor: 5.958
Authors: Joseph M Kindler; Andrea Kelly; Philip R Khoury; Lorraine E Levitt Katz; Elaine M Urbina; Babette S Zemel Journal: Diabetes Care Date: 2020-08-10 Impact factor: 19.112
Authors: Zoi Drosatos-Tampakaki; Konstantinos Drosatos; Yasemin Siegelin; Shan Gong; Salmiyeh Khan; Thomas Van Dyke; Ira J Goldberg; P Christian Schulze; Ulrike Schulze-Späte Journal: J Bone Miner Res Date: 2014 Impact factor: 6.741